Analyst Update: Cempra, Clovis Oncology, SolarCity Corp

Analysts adjusted their ratings on Cempra Inc (CEMP), Clovis Oncology Inc (CLVS), and SolarCity Corp (SCTY)

Jul 20, 2015 at 2:19 PM
facebook X logo linkedin


Analysts are weighing in today on pharmaceutical firms Cempra Inc (NASDAQ:CEMP) and Clovis Oncology Inc (NASDAQ:CLVS), as well as alternative energy provider SolarCity Corp (NASDAQ:SCTY). Here's a quick roundup of today's brokerage notes on CEMP, CLVS, and SCTY.

  • CEMP is busting out today, touching a record high of $46.14 earlier, and last seen up 8.1% at $45.47. The sharp move follows a price-target hike to $56 from $42 at Roth Capital, which waxed optimistic on the company's antibiotic, solithromycin. On a year-over-year basis, the stock has almost quintupled in value. Not surprisingly, 100% of analysts consider Cempra Inc a "strong buy" -- though there's room for future price-target hikes, as the consensus price target of $41.90 stands at a discount to current trading levels. Looking ahead, CEMP is tentatively scheduled to report second-quarter earnings next week.

  • CLVS jumped north of $91 out of the gate, but is now sitting fractionally lower at $87.02, despite Goldman Sachs adding the security to its "America's Conviction Buy List." At the same time, the brokerage trimmed its price target to $110 from $116 -- still a 26.4% premium to the stock's current perch, and in record-high territory. Options traders aren't buying the hype. During the last two weeks at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), Clovis Oncology Inc has amassed a put/call volume ratio of 2.32 -- in the 93rd annual percentile. Likewise, almost 22% of the equity's float is sold short, representing two weeks of pent-up buying demand, at CLVS' average trading volumes.

  • SCTY has soared 7.6% to trade at $56.10 -- and is now back in the black on a year-to-date basis -- thanks to a bullish note from Raymond James. Specifically, the brokerage firm said that "the theoretical value of SCTY stock would be close to $100/share," based on the cost of Sunedison' Inc's (NYSE:SUNE) Vivint Solar Inc (NYSE:VSLR) buyout agreement. SolarCity Corp short sellers may be on edge. Over 46% of the stock's float is dedicated to short interest, representing about 12 sessions' worth of trading activity, at SCTY's typical daily clip.

For other stocks in analysts' crosshairs, read Analyst Upgrades: Amazon.com, Inc., Facebook Inc, and Paypal Holdings Inc and Analyst Downgrades: Zillow Group Inc, Yelp Inc, and General Motors Company.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI